CNBX PHARMACEUTICALS INC. Debt Conversion, Converted Instrument, Amount
CNBX PHARMACEUTICALS INC. (CNBX) reported Debt Conversion, Converted Instrument, Amount of $148.56 thousand for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-06-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2026-06-24
- CNBX PHARMACEUTICALS INC. debt conversion, converted instrument, amount for the quarter ending 2026-05-31 was $28.00K.
- CNBX PHARMACEUTICALS INC. debt conversion, converted instrument, amount for the quarter ending 2024-02-29 was $92.79K.
- CNBX PHARMACEUTICALS INC. debt conversion, converted instrument, amount for the quarter ending 2023-11-30 was $65.91K.
- CNBX PHARMACEUTICALS INC. debt conversion, converted instrument, amount for the quarter ending 2023-05-31 was $221.80K.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month |
|---|---|---|---|
| 2026-05-31 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-24 | $148.56K 10-Q · filed 2026-06-24 | |
| 2026-02-28 | $120.56K 10-Q · filed 2026-04-14 | ||
| 2025-02-28 | $120.56K 10-Q · filed 2026-04-14 | ||
| 2024-05-31 | $92.79K 10-Q · filed 2024-07-15 | ||
| 2024-02-29 | $92.79K 10-Q · filed 2024-04-16 | $158.69K derived: sum of 2 quarters · filed 2024-04-16 | |
| 2023-11-30 | $65.91K 10-Q · filed 2024-01-12 | ||
| 2023-05-31 | $221.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-07-14 | $470.13K 10-Q · filed 2023-07-14 | |
| 2023-02-28 | $248.33K 10-Q · filed 2023-04-14 | ||
| 2022-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-07-14 | $225.23K 10-Q · filed 2022-07-14 | |
| 2022-02-28 | $225.23K 10-Q · filed 2022-04-12 |